Pathologically Scarred by Fibrosis: How To Model and Quantify Human NASH in a Microphysiological System
Now Available On-Demand
Non-alcoholic steatohepatitis (NASH) is a widespread disease affecting up to ~12% of the US population – characterized by lipid accumulation in hepatocytes, infiltration of immune cells and fibrosis of the liver.
Non-alcoholic steatohepatitis (NASH) is a widespread disease affecting up to ~12% of the US population – characterized by lipid accumulation in hepatocytes, infiltration of immune cells and fibrosis of the liver. Replicating liver fibrosis is a key element in any in vitro NASH model, however, it is normally poorly assessed, unquantifiable and has a limited dynamic range.
An advanced three-dimensional (3D) microfluidic NASH model has been developed using primary human cells to replicate the human biomarkers of the disease. In this webinar, we will demonstrate how the model can be fine-tuned using exogenous stimuli to enhance key features such as fibrosis or inflammation. We will furthermore discuss the development of an automated workflow to acquire and analyze confocal fluorescent images of these 3D microtissues in order support characterization of fibrosis.
Attend this webinar to learn about:
Developing an in vitro 3D microfluidic NASH model
Effects of exogenous stimuli on NASH (e.g., TGFβ, lipopolysaccharides, fructose, cholesterol)
Characterizing fibrosis using confocal microscopy
Automation of confocal imaging in a 3D in vitro model
Speaker Information:
Dr Gareth Guenigault Senior Scientist CN Bio Innovations
Dr Samantha Peel Principal Scientist, Functional Genomics, Discovery Sciences AstraZeneca
